News - vedolizumab


Current filters:


Popular Filters

Takeda's vedolizumab enters Ph III in Japan for UC and Crohn's disease

Takeda's vedolizumab enters Ph III in Japan for UC and Crohn's disease


Japan’s largest drugmaker Takeda Pharmaceutical revealed today that vedolizumab), an investigational…

Asia-PacificGastro-intestinalsPharmaceuticalResearchTakeda Pharmaceuticalsvedolizumab

FDA advisory panel backs approval of Takeda’s vedolizumab

FDA advisory panel backs approval of Takeda’s vedolizumab


A US Food and Drug Administration advisory committee has recommended approval of vedolizumab from Japan’s…

Gastro-intestinalsPharmaceuticalRegulationTakeda PharmaceuticalsUSAvedolizumab

US Priority Review for Takeda's vedolizumab for ulcerative colitis


Japan's largest drugmaker, Takeda Pharmaceutical (TYO: 4502) says that the US Food and Drug Administration…

Gastro-intestinalsNorth AmericaPharmaceuticalRegulationTakeda Pharmaceuticalsvedolizumab

Takeda's vedolizumab shows efficacy in colitis and Crohn's disease


A new investigational antibody - vedolizumab - from Japan's largest drugmaker, Takeda Pharmaceuticals…

Gastro-intestinalsPharmaceuticalResearchTakeda Pharmaceuticalsvedolizumab

Takeda files BLA for vedolizumab for Crohn's and ulcerative colitis in USA


The US subsidiary of Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) has submitted a Biologics…

Gastro-intestinalsNorth AmericaPharmaceuticalRegulationTakeda Pharmaceuticalsvedolizumab

Vedolizumab has potential to offer improvement over infliximab in UC


Surveyed US and EU5 gastroenterologists agree that new moderate to severe ulcerative colitis (UC) therapies…

EuropeGastro-intestinalsinfliximabJanssenMarkets & MarketingMerck & CoNorth AmericaPharmaceuticalRemicadeTakeda Pharmaceuticalsvedolizumab

Eisai slams German decision on Fycompa; Takeda files vedolizumab with EMA


The German Federal Joint Committee (G-BA), the decision-making body of the self-governing medical system…

EisaiEuropeFycompaGastro-intestinalsNeurologicalPharmaceuticalRegulationTakeda Pharmaceuticalsvedolizumab

US gastroenterologists' attitudes to prescribing for Crohn's disease and ulcerative colitis


When evaluating the most important attributes for emerging therapies for Crohn's disease (CD) and ulcerative…

BiotechnologyGastro-intestinalsHumiraMarkets & MarketingNorth AmericaRemicadeSimponi Injectionvedolizumab

Takeda's vedolizumab meets primary endpoints in Ph III Crohn's disease study


Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) has reported positive top-line results from…

Gastro-intestinalsPharmaceuticalResearchTakeda Pharmaceuticalsvedolizumab

Ulcerative colitis drug market to reach $3 billion by 2020


The ulcerative colitis drug market will experience moderate growth over the next decade, increasing from…

Gastro-intestinalsHumiraMarkets & MarketingPharmaceuticalRemicadeSimponi Injectiontofacitinibvedolizumab

Back to top